《分子腫瘤學(xué)》是一份開放獲取的國際期刊,重點(diǎn)介紹基礎(chǔ)、臨床和發(fā)現(xiàn)驅(qū)動(dòng)的轉(zhuǎn)化性癌癥研究的新發(fā)現(xiàn)、方法和技術(shù)進(jìn)展。工作重點(diǎn)是顯著提高我們對(duì)導(dǎo)致人類腫瘤發(fā)展的疾病過程的理解,并/或建立對(duì)癌癥患者的診斷、預(yù)后和預(yù)防策略具有明確臨床意義的新概念。主題包括但不限于:細(xì)胞周期等關(guān)鍵生物學(xué)過程;DNA修復(fù);細(xì)胞凋亡;入侵和轉(zhuǎn)移;血管生成和lymphangiogenesis;細(xì)胞信號(hào)和交互網(wǎng)絡(luò);免疫反應(yīng)。新興技術(shù)(基因組學(xué)、蛋白質(zhì)組學(xué)、功能基因組學(xué)、代謝組學(xué)、組織陣列、成像)和模型系統(tǒng)。生物標(biāo)志物:診斷、預(yù)后、分層及療效。癌癥遺傳學(xué)、表觀遺傳學(xué)和基因組不穩(wěn)定性。最小殘留病變,癌前病變。腫瘤微環(huán)境。分子病理學(xué)。腫瘤免疫學(xué)。轉(zhuǎn)化研究。癌癥治療(目標(biāo)發(fā)現(xiàn)、藥物設(shè)計(jì)、免疫治療、聯(lián)合治療、耐藥性和個(gè)體化治療)。化療,放療和手術(shù)。臨床藥理學(xué)。臨床試驗(yàn),將基礎(chǔ)科學(xué)融入癌癥臨床試驗(yàn)。分子流行病學(xué)。報(bào)道研究文章評(píng)論(僅限受邀)科學(xué)政策的文章提交作者2016年8月1日起,稿件可提交至分子腫瘤學(xué)網(wǎng)站:https://mc.criptcentral.com/molonc
Journal of Oncology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to breast cancer, lung cancer, gastrointestinal cancer, skin cancer, head and neck cancer, paediatric oncology, neurooncology as well as genitourinary cancer. The journal provides a multidisciplinary forum for translational and clinical oncology research in the areas of molecular pathology, genomics, diagnosis and therapy, with a specific focus on molecular targeted agents and novel immune therapies.Journal of Oncology is archived in Portico, which provides permanent archiving for electronic scholarly journals, as well as via the LOCKSS initiative. It operates a fully open access publishing model which allows open global access to its published content. This model is supported through Article Processing Charges. For more information on Article Processing charges in general, click here.Journal of Oncology is included in many leading abstracting and indexing databases. For a complete list, click here.Journal of Oncology has been recently accepted for indexing in the Science Citation Index Expanded and will receive its first Impact Factor in mid 2018.
SCI熱門推薦期刊 >
SCI常見問題 >
職稱論文常見問題 >
EI常見問題 >